These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 31009664)

  • 1. A pilot study of 2% tofacitinib cream with narrowband ultraviolet B for the treatment of facial vitiligo.
    McKesey J; Pandya AG
    J Am Acad Dermatol; 2019 Aug; 81(2):646-648. PubMed ID: 31009664
    [No Abstract]   [Full Text] [Related]  

  • 2. Rapid Repigmentation of Vitiligo Using Tofacitinib Plus Low-Dose, Narrowband UV-B Phototherapy.
    Kim SR; Heaton H; Liu LY; King BA
    JAMA Dermatol; 2018 Mar; 154(3):370-371. PubMed ID: 29387870
    [No Abstract]   [Full Text] [Related]  

  • 3. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure.
    Liu LY; Strassner JP; Refat MA; Harris JE; King BA
    J Am Acad Dermatol; 2017 Oct; 77(4):675-682.e1. PubMed ID: 28823882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata.
    Bayart CB; DeNiro KL; Brichta L; Craiglow BG; Sidbury R
    J Am Acad Dermatol; 2017 Jul; 77(1):167-170. PubMed ID: 28619556
    [No Abstract]   [Full Text] [Related]  

  • 5. Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy.
    Craiglow BG; King BA
    JAMA Dermatol; 2015 Oct; 151(10):1110-2. PubMed ID: 26107994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tofacitinib therapy for children with severe alopecia areata.
    Dai YX; Chen CC
    J Am Acad Dermatol; 2019 Apr; 80(4):1164-1166. PubMed ID: 30630026
    [No Abstract]   [Full Text] [Related]  

  • 7. Successful treatment of resistant lichen planopilaris with topical tofacitinib monotherapy.
    Janušonytė E; Menzinger S; Kaya G; Laffitte E
    Ann Dermatol Venereol; 2024 Sep; 151(3):103303. PubMed ID: 39154522
    [No Abstract]   [Full Text] [Related]  

  • 8. [Pharmacology profile and clinical findings of tofacitinib citrate (Xeljanz® tablet 5 mg)].
    Harada T; Nakamura H
    Nihon Yakurigaku Zasshi; 2014 Sep; 144(3):133-41. PubMed ID: 25213614
    [No Abstract]   [Full Text] [Related]  

  • 9. Tofacitinib cream plus narrowband ultraviolet B phototherapy for segmental vitiligo in a child.
    Olamiju B; Craiglow BG
    Pediatr Dermatol; 2020 Jul; 37(4):754-755. PubMed ID: 32255214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tofacitinib Treatment for Pretibial Myxedema.
    Wang S; Chen X; Bai J; Sun Q; Fang H; Qiao J
    JAMA Dermatol; 2024 May; 160(5):578-580. PubMed ID: 38568614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo.
    Vu M; Heyes C; Robertson SJ; Varigos GA; Ross G
    Clin Exp Dermatol; 2017 Dec; 42(8):942-944. PubMed ID: 29034491
    [No Abstract]   [Full Text] [Related]  

  • 12. Partial repigmentation of vitiligo with tofacitinib, without exposure to ultraviolet radiation.
    Komnitski M; Komnitski A; Komnitski Junior A; Silva de Castro CC
    An Bras Dermatol; 2020; 95(4):473-476. PubMed ID: 32418716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tofacitinib in the Treatment of Rheumatoid Arthritis and Chronic Plaque Psoriasis.
    Gupta AK; Cernea M; Lynde CW
    Skin Therapy Lett; 2017 Mar; 22(2):1-7. PubMed ID: 28329404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot study of tofacitinib for refractory Behçet's syndrome.
    Liu J; Hou Y; Sun L; Li C; Li L; Zhao Y; Zeng X; Zhang F; Zheng W
    Ann Rheum Dis; 2020 Nov; 79(11):1517-1520. PubMed ID: 32461206
    [No Abstract]   [Full Text] [Related]  

  • 15. Topical tofacitinib for patients with lichen planopilaris and/or frontal fibrosing alopecia.
    Chen LC; Ogbutor C; Kelley KJ; Senna MM
    J Am Acad Dermatol; 2024 Jun; 90(6):1260-1262. PubMed ID: 38311243
    [No Abstract]   [Full Text] [Related]  

  • 16. Medical and Maintenance Treatments for Vitiligo.
    Passeron T
    Dermatol Clin; 2017 Apr; 35(2):163-170. PubMed ID: 28317526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of tofacitinib, an oral janus kinase inhibitor, on clinical signs of moderate-to-severe plaque psoriasis in different body regions.
    Menter A; Papp KA; Tan H; Tyring S; Wolk R; Buonanno M
    J Drugs Dermatol; 2014 Mar; 13(3):252-6. PubMed ID: 24595567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients.
    Liu LY; Craiglow BG; King BA
    J Am Acad Dermatol; 2018 Feb; 78(2):403-404.e1. PubMed ID: 29108908
    [No Abstract]   [Full Text] [Related]  

  • 19. Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes.
    Panés J; Su C; Bushmakin AG; Cappelleri JC; Mamolo C; Healey P
    BMC Gastroenterol; 2015 Feb; 15():14. PubMed ID: 25651782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.
    Gladman D; Rigby W; Azevedo VF; Behrens F; Blanco R; Kaszuba A; Kudlacz E; Wang C; Menon S; Hendrikx T; Kanik KS
    N Engl J Med; 2017 Oct; 377(16):1525-1536. PubMed ID: 29045207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.